Настоящее и будущее анти-Her-2-терапии рака молочной железы
https://doi.org/10.17650/1994-4098-2011-0-2-41-44
Аннотация
В статье представлен новый класс противоопухолевых препаратов молекулярно-направленного действия (таргетных), мишенью которых являются молекулы, принимающие участие в канцерогенезе. Рассмотрены основные препараты данного класса и их комбинации, проведена оценка эффективности применения их в терапии рака молочной железы.
Список литературы
1. Gasparini G., Longo R., Torino F. et al. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005;16(Suppl 4):28–36.
2. Roskoski R. Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1–11.
3. Stern D.F. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000;2:176–83.
4. Lin N.U., Winer E.P. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 2004;6:204–10.
5. Riese D.J. 2nd, Stern D.F. Specificity within the EGF family/ErbB receptorfamily signaling network. Bioessays 1998;20:41–8.
6. Mills G.B., Lu Y., Fang X. et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001;28(Suppl 16):125–41.
7. Salomon D.S., Brandt R., Ciardiello F. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.
8. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 1987;235:177–82.
9. Tsutsui S., Ohno S., Murakami S. et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002;71:67–75.
10. Slamon D.J., Godolphin W., Jones L.A. et al. Studies of the HER-2/neu proto- oncogene in human breast and ovarian cancer. Science 1989;244:707–12.
11. Cho H.S., Mason K., Ramyar K.X. et al. Structure of the extracellular regionof HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756–60.
12. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
13. Smith I., Procter M., Gelber R.D. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.
14. Romond E.H., Perez E.A., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84.
15. Nahta R., Yu D., Hung M.C. et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269–80.
16. Pegram M.D. Challenges in HER2- positive breast cancer. Educational book. ASCO 2011:8–13.
17. Geyer C.E., Forster J., Lindquist D. et al. Lapatinib plus capecitabine for Her- 2-positive advanced breast cancer. N Engl J Med 2006;355:2733–43.
18. Cameron D., Casey M., Press M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112(3):533–43.
19. Johnston S., Pippen J.Jr., Pivot X. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol
20. ;27(33):5538.
21. Lin N.U., Carey L.A., Liu M.C. et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993–9.
22. Boccardo F., Kaufman B., Baselga J. et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2-breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU). J Clin Oncol 2008;26(15 Suppl):64; abstr 1094.
23. Lin N.U., Diéras V., Paul D. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2- positive breast cancer. Clin Cancer Res 2009;15:1452–9.
24. www.clinicaltrials.gov
25. Rugo H.S., Franco S., Munster P. et al. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). J Clin Oncol 2008;26(15 Suppl):51; abstr 1042.
26. Slamon D., Gomez H.L., Kabbinavar F.F. et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. J Clin Oncol 2008;26(15 Suppl):45; abstr 1016.
27. O’Shaughnessy J., Blackwell K.L., Burstein H.J. et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008;26(15 Suppl):44; abstr 1015.
28. Bernard-Marty C., Lebrun F., Awada A., Piccart M.J. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006;66:1577–91.
29. Agus D.B., Gordon M.S., Taylor C. et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534–43.
30. Hayes D.F., Yamauchi H., Broadwater G. et al. for the Cancer and Leukemia Group B. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001;7:2703–11.
31. Baselga J., Gelmon K.A, Verma S. et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during
32. prior trastuzumab therapy. J Clin Oncol 2010;28(7):1138–44.
33. Cortés J., Baselga J., Petrella T. et al. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2-positive breast cancer. J Clin Oncol 2009;27(15):1022.
34. Rabindran S.K., Discafani C.M., Rosfjord E.C. et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958–65.
35. Wong K.K., Fracasso P.M., Bukowski R.M. et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552–8.
36. Krop I.E., Mita M., Burris H.A. et al. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. Presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10–14, 2008 San Antonio, TX. J Clin Oncol 2008;26(15 Suppl):1029; abstr 3136.
Рецензия
Для цитирования:
Летягин В.П. Настоящее и будущее анти-Her-2-терапии рака молочной железы. Опухоли женской репродуктивной системы. 2011;(2):41-44. https://doi.org/10.17650/1994-4098-2011-0-2-41-44
For citation:
Letyagin V.P. Present and future of breast cancer anti-Her-2-therapy. Tumors of female reproductive system. 2011;(2):41-44. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-2-41-44
Просмотров:
424
Послать статью по эл. почте 